Imperial Brands PLC (IMB.L) Bundle
Curious how Imperial Brands PLC is stacking up for investors? The company posted a tobacco & NGP net revenue of £8.32bn for FY25 (a 4.1% increase) even as reported group revenue slipped 0.7% to £32.17bn on adverse FX-backed by a standout 15.4% jump in NGP net revenue in H1 driven by oral nicotine gains-and delivered adjusted operating profit of £3.99bn (margin 47.9%) with adjusted EPS at 315.0p and free cash flow of £2.7bn (cash conversion 97%), while balance sheet metrics show adjusted net debt of £8.4bn (adjusted net debt/EBITDA 2.0x), reported net debt of £9.0bn and a progressive dividend at 160.32p (+4.5%), alongside a £1.45bn FY26 buyback; valuation sits at about 8.5x P/E with a 5.5% yield and five‑year total shareholder return of 241%-read on for detailed breakdowns of revenue mix, profitability, leverage, liquidity, valuation and the key risks and opportunities shaping the stock.
Imperial Brands PLC (IMB.L) - Revenue Analysis
Imperial Brands PLC (IMB.L) reported mixed top-line results for the fiscal year ending 30 September 2025, with strong performance in tobacco pricing and next-generation products (NGPs) offset by adverse foreign exchange impacts on reported consolidated revenue.- FY25 tobacco and NGP net revenue: £8.32 billion, up 4.1% (driven by tobacco pricing and NGP growth).
- FY25 reported consolidated revenue: £32.17 billion, down 0.7% (negative FX translation effect).
- FY25 adjusted revenue (core tobacco & NGP focus): +1.9% to £8.32 billion, reflecting resilience in priority markets.
- H1 2025 tobacco and NGP net revenue at constant currency: +3.2% (tobacco +2.7%, NGP +15.4%).
- NGP momentum: FY25 NGP growth of 13.7%; H1 2025 NGP net revenue +15.4% driven by oral nicotine in the U.S. and Europe.
- Market share: stable across the five priority markets despite reported revenue decline.
| Metric | Period | Value | YoY Change |
|---|---|---|---|
| Tobacco & NGP net revenue | FY25 | £8.32 billion | +4.1% |
| Reported consolidated revenue | FY25 | £32.17 billion | -0.7% |
| Adjusted revenue (core focus) | FY25 | £8.32 billion | +1.9% |
| NGP net revenue (H1 2025) | H1 2025 | - | +15.4% |
| Tobacco revenue (H1 2025) | H1 2025 | - | +2.7% (constant currency) |
| NGP FY25 growth | FY25 | - | +13.7% |
- NGP growth concentrated in oral nicotine products in the U.S. and Europe; share gains across smoke-free categories.
- Tobacco pricing actions supported revenue per unit in core markets, offsetting volume pressures.
- Adverse foreign exchange translation reduced reported consolidated revenue by c.0.7% despite underlying operational growth.
- Stable market share across five priority markets underscores resilience of the traditional tobacco franchise while NGPs drive diversification.
Imperial Brands PLC (IMB.L) - Profitability Metrics
Imperial Brands delivered a solid FY25 performance with expanding margins, EPS growth on an adjusted basis, robust cash generation and improved returns on invested capital driven by strong tobacco pricing, growth in next-generation products (NGPs) and disciplined capital management.- Adjusted operating profit: £3.99bn in FY25, up 4.6% and slightly above consensus (£3.98bn).
- Adjusted operating profit margin: 47.9% in FY25 (FY24: 46.8%).
- Adjusted EPS: 315.0p in FY25, up 6.1% (benefiting from profit growth and reduced share count).
- Reported EPS: 251.1p in FY25, down 16.5% (driven by higher tax charges; partly offset by lower finance costs and lower share count).
- ROIC: 20.7% in FY25, improving by 100 basis points year-on-year (lower average invested capital contributed to the increase).
- Free cash flow: £2.7bn in FY25, supporting shareholder returns and capital allocation flexibility.
| Metric | FY24 | FY25 | YoY Change |
|---|---|---|---|
| Adjusted operating profit | £3.81bn | £3.99bn | +4.6% |
| Adjusted operating profit margin | 46.8% | 47.9% | +110 bps |
| Adjusted EPS | 297.0p | 315.0p | +6.1% |
| Reported EPS | 300.7p | 251.1p | -16.5% |
| ROIC | 19.7% | 20.7% | +100 bps |
| Free cash flow | £2.5bn | £2.7bn | +£0.2bn |
- Drivers: tobacco price realization and NGP growth lifted margins and operating profit; a lower average invested capital base amplified ROIC improvements.
- Cash & returns: £2.7bn FCF enabled increased shareholder distributions and deleveraging potential while supporting ongoing investment in growth categories.
- EPS divergence: adjusted EPS rose on operational gains and share reduction; reported EPS fell due to elevated tax charges despite lower finance costs.
Imperial Brands PLC (IMB.L) - Debt vs. Equity Structure
Imperial Brands' capital structure in FY25 reflects a balance between deleveraging targets and active shareholder returns, supported by strong cash generation and ongoing investment in growth.- Adjusted net debt rose to £8.4bn in FY25 (from £7.7bn in FY24), producing an adjusted net debt/EBITDA of 2.0x - at the low end of the 2.0x-2.5x target range.
- Reported net debt increased to £9.0bn in FY25 (from £8.3bn in FY24), driven by growth investments and distributions to shareholders.
- Dividend policy remains progressive: FY25 dividend per share increased by 4.5% to 160.32p.
- Capital returns over the past five years total c. £10.0bn, including share buybacks and dividends.
- FY26 buyback program announced at £1.45bn (a 13.6% increase over FY25 buybacks), signalling confidence in cash flow and commitment to shareholder value.
- Leverage metrics showed mid-year improvement: adjusted net debt/EBITDA in H1 2025 improved to 2.4x from 2.5x in H1 2024.
| Metric | FY24 | FY25 | H1 2024 | H1 2025 |
|---|---|---|---|---|
| Adjusted Net Debt (£bn) | 7.7 | 8.4 | 7.7 | 8.4 |
| Reported Net Debt (£bn) | 8.3 | 9.0 | 8.3 | 9.0 |
| Adjusted Net Debt / EBITDA (x) | - | 2.0 | 2.5 | 2.4 |
| Dividend per Share (p) | 153.46 (approx) | 160.32 | - | - |
| Five‑year Capital Returns (£bn) | 10.0 | - | ||
| Share Buybacks | FY25: £1.25bn | FY26 announced: £1.45bn | - | - |
- Implications for investors: leverage sits at the lower bound of target range (FY25 adjusted 2.0x), providing headroom for further buybacks and dividends while still allowing for strategic investment and M&A.
- Management signal: the larger FY26 buyback and progressive dividend increase underscore priority on returning capital alongside maintaining an investment-grade leverage profile.
Imperial Brands PLC (IMB.L) - Liquidity and Solvency
Imperial Brands reported robust liquidity and improving solvency metrics in FY25 driven by strong cash generation and disciplined balance sheet management. Free cash flow of £2.7 billion, combined with a cash conversion rate of 97%, underpins the group's capacity to fund operations, capital allocation and shareholder returns.- Free cash flow (FY25): £2.7 billion; cash conversion: 97%
- Adjusted net debt / EBITDA (FY25): 2.0x - at the low end of target range
- Reported net debt (FY25): £9.0 billion; net debt / equity: 1.2x
- Adjusted net debt reported as £8.4 billion in FY25 (from £8.3 billion in FY24)
- Diversified revenue mix: continued contribution from Next Generation Products (NGPs) alongside stable tobacco sales
| Metric | FY24 | FY25 |
|---|---|---|
| Free cash flow | £2.1 billion | £2.7 billion |
| Cash conversion rate | 88% | 97% |
| Adjusted net debt | £8.3 billion | £8.4 billion |
| Reported net debt | £8.7 billion | £9.0 billion |
| Adjusted net debt / EBITDA | 2.3x | 2.0x |
| Net debt / equity | 1.1x | 1.2x |
| Dividend coverage (cash basis) | Covered | Covered |
- Strong cash flow and near-100% conversion support the progressive dividend policy and ongoing share buyback programmes.
- Leverage at 2.0x adjusted net debt/EBITDA keeps the business within conservative targets, providing flexibility for M&A or further capital returns.
- Diversified revenues (NGPs growth plus stable tobacco) reduce single-product risk and bolster liquidity resilience.
- Reported net debt and net debt/equity indicate a balanced capital structure, while adjusted net debt movements reflect active debt management.
Further context and investor-focused analysis: Exploring Imperial Brands PLC Investor Profile: Who's Buying and Why?
Imperial Brands PLC (IMB.L) - Valuation Analysis
Imperial Brands presents a value-oriented profile driven by below-average earnings multiples, robust cash generation and shareholder returns.- P/E (2025E): 8.5x - below five‑year average of 10.2x, implying potential undervaluation versus historical norms.
- Dividend yield (FY25): 5.5% - supported by a 4.5% increase in FY25 dividend per share.
- Total shareholder return (5y): 241% - strong multi‑year value creation for holders.
- ROIC (FY25): 20.7% - improved from 19.7% in FY24, indicating more efficient capital deployment.
- Free cash flow (FY25): £2.7bn - underpins reinvestment capacity and distributions.
- Share buyback (FY26): £1.45bn - a 13.6% increase versus prior year, signaling management confidence.
| Metric | FY24 | FY25 | Notes |
|---|---|---|---|
| P/E (based on EPS est.) | - | 8.5x | Below 5‑yr avg 10.2x |
| 5‑yr Avg P/E | 10.2x | Historical comparator | |
| Dividend yield | 5.3% | 5.5% | Yield reflects 4.5% DPS increase in FY25 |
| Dividend per share change | - | +4.5% | FY25 increase |
| Total shareholder return (5y) | 241% | Including price appreciation and dividends | |
| ROIC | 19.7% | 20.7% | Improved operational returns in FY25 |
| Free cash flow | £2.4bn | £2.7bn | FY25 cash generation |
| Share buyback (FY26) | £1.28bn | £1.45bn | 13.6% increase year‑on‑year |
Imperial Brands PLC (IMB.L) - Risk Factors
Imperial Brands PLC (IMB.L) faces a suite of interrelated risks that can materially affect revenue, margins and cash generation. Below are the principal risk areas with quantified scenario illustrations and contextual data to help investors assess vulnerability and potential outcomes.- Regulatory risk: menthol and flavour bans
- Declining smoking prevalence
- Foreign exchange (FX) and reported results
| FX Driver | Illustrative Exposure | Potential Reported Impact |
|---|---|---|
| GBP weakness vs USD/EUR | ~30-50% of revenues sourced in USD/EUR (group estimate) | Reported revenue and profit increase; translation tailwind of low-single to mid-single digit % on reported top line per 5-10% FX move |
| GBP strength vs USD/EUR | Same exposure | Reported revenue and profit contraction; translation headwind of similar magnitude |
| Transactional FX on supply costs | Procurement and distribution denominated in foreign currencies | Margin pressure if costs rise and cannot be fully passed through |
- Competitive pressures in the Next Generation Products (NGP) market
- Supply chain and logistics disruptions
| Event | Short-term P&L impact | Operational effect |
|---|---|---|
| Freight cost spike (e.g., +30%) | Incremental cost pressure of low-to-mid single-digit % on logistics line; partially pass-throughable | Need to increase inventory or accept reduced fill rates |
| Supplier outage for key input | One-off production disruptions, potential revenue loss in affected markets (0.5-2% of group sales per prolonged outage) | Short-term SKU unavailability; potential brand switching |
- Changes in consumer preferences and health trends
| Trend | Potential sales effect (annual) | Investor implication |
|---|---|---|
| Accelerated cessation (2-3% faster decline in smoking prevalence) | Combustible revenue decline of several percentage points over 3-5 years | Pressure on legacy EBITDA unless offset by NGP margin expansion |
| Rapid NGP conversion with price competition | NGP revenue grows but blended gross margin may compress by low-to-mid single-digit % | Need for scale, cost control and product differentiation |
- NGP and diversified revenue: management has publicly targeted material growth in NGP share versus combustible legacy-monitoring NGP contribution to group sales is essential.
- Margin sensitivity: a 1-3% mix shift from combustible to lower-margin NGP could reduce group adjusted operating margin by up to several hundred basis points absent cost offset.
- Cash flow and leverage: operating cash flow volatility from any of the above risks can affect the company's ability to sustain buybacks, dividends and M&A-track adjusted operating profit and free cash flow trends quarter-to-quarter.
- Regulatory monitoring: track country-level consultations and timelines for flavour/menthol restrictions (U.S. FDA, U.K./EU proposals).
- FX hedging and reporting: review Imperial's hedging disclosures and sensitivity tables in periodic reports to quantify translation vs transactional exposure.
- Competitive KPIs: follow share trends in key NGP categories and price/mix disclosures in quarterly trading updates.
- Supply chain transparency: assess inventory days, supplier concentration metrics and freight cost pass-through mechanisms in management commentary.
Imperial Brands PLC (IMB.L) - Growth Opportunities
Imperial Brands is pivoting from a predominantly combustible tobacco business toward next-generation products (NGPs) and selective geographic growth to sustain revenue and margin expansion. Key numerical highlights and strategic moves driving this shift include a £1.45 billion share buyback program for FY26, announced increases in dividend distributions, and targeted product launches such as the Pulze 3.0 heated tobacco device slated for late 2025. These actions align capital return with reinvestment in higher-growth categories.- Shareholder returns: £1.45bn share buyback program for FY26, plus a progressive dividend policy with year-on-year increases (company-announced uplift in dividend per share alongside the buyback).
- NGP commercialization: Launch pipeline includes Pulze 3.0 (heated tobacco) in late 2025 and new e-vapor products to broaden the NGP portfolio and consumer appeal.
- Geographic rebalancing: Market share gains are expected in the U.S., Germany and Australia, intended to offset declines in Spain and the UK.
| Metric | Most Recent Reported / Baseline | Near-term Target / FY26 Guidance |
|---|---|---|
| Total revenue (approx.) | £7.6bn (latest reported baseline) | £7.8-8.2bn (near-term projection, reflecting NGP uplift) |
| NGP revenue (% of group) | ~12% (~£0.9bn) | 15-18% (~£1.2-1.5bn) driven by new product launches |
| Share buybacks | - | £1.45bn (FY26 program) |
| Dividend policy | Progressive policy with recent increase announced | Continued increases expected; policy underpinned by buybacks and cash flow |
| Targeted market shifts | Market share decline in Spain/UK | Market share gains planned in U.S., Germany, Australia |
- Product cadence: New device launches (Pulze 3.0 and updated e-vapor SKUs) late‑2025 → supports higher ASPs and replacement cycle monetization.
- Revenue mix shift: If NGP share grows from ~12% to 15-18% by FY26, incremental NGP revenue could reach £300-£600m versus baseline.
- Margin benefits: NGPs typically carry higher gross margins than low-price combustible segments, enabling margin accretion even with modest volume growth.
- Buybacks + dividends: The £1.45bn buyback for FY26 combined with a progressive dividend policy signals management confidence in cash generation and balance sheet strength.
- Cash flow support: Operational cash flow and working-capital discipline are central to funding both NGP investment and shareholder returns without large leverage increases.
- Valuation impact: Market recognition of successful NGP rollouts and sustained buybacks could compress discount multiples applied to legacy tobacco earnings.
- Regulatory changes in core markets (flavor bans, device restrictions) that could impact NGP adoption.
- Competitive responses in NGPs - pricing and distribution moves by major rivals could pressure share gains.
- Execution timing - delayed launches or slower-than-expected consumer migration would compress near-term upside.
Imperial Brands PLC (IMB.L) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.